NASDAQ · SURF
Surface Oncology, Inc.
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
Loading market information…
NASDAQ · ACHL · USD
Stock price, earnings
Quote as of Mar 20, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Achilles Therapeutics plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2023 |
|---|
| May 10, 2023 |
| -$0.44-7.32% vs estimate |
| $0.00 |
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
$0.76$0.00 (0.0%)
The Valens Company Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.63% below the high.
$2.38+$0.01 (+0.42%)
Heat Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 4.03% below the high.
$18.20+$16.47 (+952.02%)
Reneo Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.05% below the high.
$0.68-$0.05 (-6.41%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.81% below the high.
$1.48$0.00 (0.0%)
TCR2 Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.86% below the high.
$22.47-$0.59 (-2.56%)
Sigilon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.75% below the high.
$0.88+$0.01 (+1.49%)
Kronos Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
